摘要
目的观察美沙拉嗪联合双歧三联活菌胶囊治疗溃疡性结肠炎患者的临床疗效及安全性。方法选取80例溃疡性结肠炎患者,按随机数字表法分为对照组、试验组,各40例。对照组口服美沙拉嗪肠溶片,每次1.0 g,每天3次,试验组在对照组的基础上给予双歧三联活菌胶囊,每次0.42 g,每天3次,口服。2组均连续治疗1个月。比较2组患者的临床疗效;比较2组治疗前后腹痛、腹泻和黏液样便症状评分;以酶联免疫吸附(ELISA)法检测2组血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL^-10)水平;以比色法检测血清丙二醛(MDA)及超氧化物歧化酶(SOD)水平。统计2组治疗期间药物不良反应发生情况。结果治疗后,对照组与试验组临床总有效率分别为75.00%,95.00%,差异有统计学意义(P<0.05)。治疗后,对照组与试验组腹痛评分分别为(1.32±0.41),(0.74±0.28)分,腹泻评分分别为(1.64±0.61),(0.86±0.34)分,黏液样便症状评分分别为(2.55±0.73),(1.67±0.68)分,血清SOD分别为(1.52±0.21),(1.76±0.24)U·mL^-1,MDA分别为(7.02±0.62),(5.98±0.63)nmol·mL^-1,hs-CRP含量分别(7.38±1.36),(5.13±1.01)mg·L^-1,TNF-α含量分别为(36.42±10.12),(18.29±7.35)ng·L^-1,IL^-10含量分别为(55.19±6.16),(72.21±7.12)ng·L^-1,差异均有统计学意义(均P<0.05)。治疗期间,对照组与试验组的药物不良反应发生率分别为25.00%,5.00%,差异有统计学意义(P<0.05)。结论美沙拉嗪联合双歧三联活菌胶囊可有效改善溃疡性结肠炎患者临床症状,抑制其氧化应激反应及炎性反应,提高临床疗效,且具有良好的安全性。
Objective To observe the clinical effect and safety of mesalazine combined with bifidotrichoderma capsule in the treatment of patients with ulcerative colitis.Methods Eighty ulcerative colitis patients were selected and divided into control group and treatment group according to random number table method, 40 cases in each group. Patients in control group were treated with mesalazine sausage tablets(1.0 g per time, 3 times per day, orally, patients in treatment group were treated with bifidotrichoderma capsule(0.42 g per time, 3 times per day, orally, on the basis of control group. Two groups were treated for 1 month. The clinical effect of the two groups were compared;the symptom scores of abdominal pain, diarrhea, and mucus-like stool symptom scores of the two groups before and after treatment were evaluated;the levels of high-sensitivity C-reactive protein( hs-CRP),tumor necrosis factor-α( TNF-α),interleukin-10( IL-10) were detected by enzyme linked immunosorbent assay( ELISA);the serum malondialdehyde( MDA) and superoxide dismutase( SOD) were detected by colorimetry method;the adverse reactions occurred during the treatment of two groups were observed. Results The clinical total effective rates in control group and treatment group were 75. 00%,95. 00%,with significant difference( P < 0. 05). After treatment,the abdominal pain scores of control group and treatment group were 1. 32 ± 0. 41,0. 74 ± 0. 28,diarrhea scores were 1. 64 ± 0. 61,0. 86 ± 0. 34,mucus-like stool symptoms scores were 2. 55 ± 0. 73,1. 67 ± 0. 68, serum SOD were( 1. 52 ± 0. 21),( 1. 76 ± 0. 24) U · mL-1,MDA were( 7. 02 ± 0. 62),( 5. 98 ± 0. 63) nmol· mL-1,the hs-CRP were( 7. 38 ± 1. 36),( 5. 13 ± 1. 01) mg · L-1,TNF-α were( 36. 42 ± 10. 12),( 18. 29 ± 7. 35) ng·L-1,IL-10 were( 55. 19 ± 6. 16),( 72. 21 ± 7. 12) ng·L-1,all with significant difference( all P < 0. 05). The incidence of adverse drug reactions in control group and treatment group during the treatment were 25. 00%,5. 00%,with significant difference( P < 0. 05). Conclusion Mesalazine combined with bifidotrichoderma capsule can effectively improve clinical symptoms of ulcerative colitis patients,inhibit the oxidative stress and inflammatory reaction,improve the clinical effect,with good safety.
作者
宋桃燕
李永烽
SONG Tao-yan;LI Yong-feng(Department of Gastroenterology,Zhuji People’s Hospital,Zhuji Hospital Affiliated To Shaoxing College of Arts and Sciences,Zhuji 311800,Zhejiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第12期1610-1613,共4页
The Chinese Journal of Clinical Pharmacology
